Nuvation Bio Inc.
NUVB
$2.13
-$0.065-2.97%
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 245.46% | 142.64% | 59.17% | 19.45% | -12.53% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 587.05% | 501.57% | 443.60% | 407.11% | -20.81% |
| Operating Income | -575.33% | -493.68% | -441.51% | -405.76% | 20.81% |
| Income Before Tax | -780.50% | -649.24% | -542.39% | -464.87% | 34.18% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -780.50% | -649.24% | -542.39% | -464.87% | 34.18% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -780.50% | -649.24% | -542.39% | -464.87% | 34.18% |
| EBIT | -575.33% | -493.68% | -441.51% | -405.76% | 20.81% |
| EBITDA | -575.95% | -494.32% | -442.14% | -406.41% | 20.86% |
| EPS Basic | -645.37% | -551.03% | -473.22% | -410.13% | 34.51% |
| Normalized Basic EPS | -645.65% | -552.06% | -475.20% | -412.99% | 33.84% |
| EPS Diluted | -640.38% | -551.75% | -473.88% | -410.74% | 33.99% |
| Normalized Diluted EPS | -645.65% | -552.06% | -475.20% | -412.99% | 33.84% |
| Average Basic Shares Outstanding | 36.31% | 22.70% | 9.29% | 3.13% | 0.42% |
| Average Diluted Shares Outstanding | 36.31% | 22.70% | 9.29% | 3.13% | 0.42% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |